Blood Test and PSMA PET Scan Study in Prostate Cancer Patients
Compares blood cell markers with PSMA PET scan results in men with prostate cancer.
Key facts
- Who runs it
- Institut Claudius Regaud
- Where
- Toulouse, FranceSee the site
- Trial code
- Registry title
- Prostate Cancer Burden and Heterogeneity Evaluation Towards Liquid Biopsy: a Correlation Study to 18FDCFPyL PET and Patients Outcome
- Status
- Recruiting
- People taking part
- 80 people, planned
- Started
- 28 Oct 2025
- Expected to end
- Oct 2028
- Type of study
- Interventional
- Treatments tested
- Patients with 18F-PET-PSMA indication
- Record updated
- 18 November 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men with prostate cancer who are due to have an 18F-PET-PSMA scan. A blood sample is taken before the scan.
- Age
- 18 years or older
- Sex
- Men only
- Disease stage
- Adenocarcinoma of the prostate confirmed by tissue examination. The scan must be indicated as part of the extension work-up.
Main reasons for not taking part
- A reason that rules out the 18F-PET-PSMA scan
- Established neuroendocrine prostate cancer
- Another cancer known to show a lot of PSMA (kidney cancer, salivary gland tumors)
- A personal, family, geographic or social situation that prevents consent or following the study, in the investigator's judgment
- Under legal protection or deprived of freedom by administrative or legal decision
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Age ≥ 18 years
- Histologically confirmed adenocarcinoma of the prostate
- Indication for 18F-PET-PSMA imaging
- Signed written informed consent
- Patient able to participate and willing to give informed consent prior performance of any study-related procedures and to comply with the study protocol
- Patient affiliated to a Social Health Insurance in France
Who cannot take part
- Concurrent malignancy known to express a significant amount of PSMA (renal cancer, salivary gland tumors)
- Patient with an established neuro endocrine prostate cancer
- Patients with a contraindication to 18F-PET-PSMA
- Any psychological, familial, geographic or social situation, according to the judgment of investigator, potentially preventing the provision of informed consent or compliance to study procedure
- Patient who has forfeited his freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice)
Where in France
- IUCT-OToulouse, FranceContact: Thibaut CASSOU-MOUNATTaking people
About the trial
What the trial wants to find out
This is a prospective, monocentric, proof of concept study aims to identify in prostate cancer patients, a potential relationship between CTC-PSMA positivity and 18F-PET-PSMA results as well as patient outcome.
Read full original descriptionShow less
Patients with 18F-PET-PSMA indication will perform imaging extension work-up as part of current practice. If they agree to participate in the study, a blood sample will be performed prior to the 18F-PET-PSMA standard imaging (T1).
In order to evaluate the potential relationship between CTC-PSMA and 18F-PET-PSMA imaging, the study will be presented to all patients seen in consultation for an extension workup for prostate cancer. This will allow to analyze the results in patients with different level of tumor burden afterward to define the following three groups based on imaging results:
Group 1 : no tumor volume Negative 18F-PET-PSMA (patients without uptake lesion)
Group 2 : low or medium tumor volume Positive 18F-PET-PSMA (patients with an uptake in prostate bed or with an oligo-metastatic extension (number of lesions < 6))
Group 3 : high tumor volume Positive 18F-PET-PSMA (patients with a polymetastastatic extension (number of lesions ≥ 6)).
In each of these groups, the rate of patients with positive PSMA CTC will be analyzed (i.e. patient having at least one CTC-PSMA positive).
For patients with an indication of treatment by 177LuPSMA-617 (PLUVICTO®) according to standard practices, additional blood samples will also be collected at the following time points: 2nd cycle (T2) and 4th cycle of treatment (T3), just before injection. For these patients, data will be collected up to 6 months after the last treatment injection (clinical and biological data; results of tumor assessments based on 18F-PET-PSMA imaging).
The group in the trial
- Patients with prostate cancerOther group
Treatment: Patients with 18F-PET-PSMA indication
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Prostate Cancer Burden and Heterogeneity Evaluation Towards Liquid Biopsy: a Correlation Study to 18FDCFPyL PET and Patients Outcome
- Plain-language title
- Blood Test and PSMA PET Scan Study in Prostate Cancer PatientsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 18 November 2025